RPRX On Track Across The Pond, CERC Gets Funded, Data Gives FOMX A Facelift

Shares of Foamix Pharmaceuticals Ltd. (FOMX) rose over 15% on Monday, following positive topline results from its phase II trial evaluating FMX-103 topical Minocycline foam for moderate-to-severe papulopustular rosacea.

from RTT - Biotech http://ift.tt/2cJgVCy
via IFTTT